NCT07919119
Risk Stratification Value of Deep NGS-MRD Detection in Acute Myeloid Leukemia Patients After Allo-HSCT
StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
6-month cumulative incidence of relapse
Timeframe: 6 months after transplantation
Secondary (6)
1 year cumulative incidence of relapse
2 year cumulative incidence of relapse
Relapse free survival
Overall survival
Non-relapse mortality
Show 1 moreShow less
Time interval from NGS-MRD positivity to clinical relapse
Arms and interventions
NGS-MRD AML cohort
This prospective, single-center, observational cohort study plans to enroll 169 high-risk acute myeloid leukemia (AML) patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). Deep NGS-MRD testing will be conducted at approximately +3 months after transplantation.
Other: NGS-MRD AML cohort
Sites
1 site in 1 country
- National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College HospitalTianjin, Tianjin Municipality, China